1. France Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Median Technologies S.A.

Median Technologies S.A.

ALMDT.PA
Median Technologies S.A.undefined flagEuronext Paris
4.69
EUR
+0.02
- -
172.33MMarket Cap
Median Technologies S.A.
ALMDT.PA
(Euronext Paris)

Recent

price

4.69

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.2
0.13
0.15
0.12
0.19
0.39
0.55
0.64
0.53
0.74
1.11
1.33
1.5
1.21
1.24
0.64
Revenue per Share
-0.59
-0.63
-0.67
-0.37
-0.54
-0.55
-0.78
-1.44
-1.27
-0.66
-1.06
-1.25
-1.28
-1.25
-1.36
-0.93
Basic EPS, GAAP
- -
- -
- -
-0.73
-0.42
-0.41
-0.69
-1.19
-1.32
-0.38
-0.48
-0.69
-1.09
-1.17
-1.03
-0.49
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-3.33
-3.81
- -
-0.18
-0.49
-0.5
-0.73
-1.39
-1.22
-0.61
-1.01
-1.2
-1.23
-1.2
-1.31
-0.88
Book Value per Share
-0.48
0.87
- -
0.15
1.46
2.6
3.31
2.07
0.75
0.1
-0.94
0.31
-0.52
-0.66
-1.95
-1.01
Tangible Book Value per Share
6
6
6
6
8
10
12
12
12
12
12
15
16
18
18
37
Basic Weighted Avg Shares
1
1
1
1
2
4
6
8
6
9
13
21
24
22
23
23
Sales/Revenue/Turnover
-306.89
-673.23
-577.76
-304.39
-290.27
-145.3
-144.74
-221.25
-241.51
-88.16
-64.72
-55.67
-97.91
-102.98
-97.46
-68.23
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
2
3
Depreciation Expense
-3
-4
-4
-2
-4
-6
-9
-17
-15
-8
-13
-19
-20
-23
-25
-34
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-291.1
-492.3
-448.74
-304.39
-290.72
-142.27
-143.39
-223.86
-241.07
-89.2
-94.98
-93.89
-85.4
-103.4
-109.99
-145.85
Profit Margin (%)
3
9
- -
2
14
28
40
25
9
1
3
20
8
9
-24
-15
Working Capital
1
- -
- -
1
1
- -
- -
- -
- -
1
16
16
18
19
9
19
LT Debt
-3
5
- -
1
12
26
39
25
9
1
-11
5
-7
-10
-34
-35
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-123.94%
-22.99%
3.49%
Free Cash Flow
29.57%
30.7%
-4.5%
Net Income, GAAP
26.91%
22.8%
34.98%
Sales/Revenue/Turnover
22.53%
13.32%
1.79%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
22
2024
- -
- -
- -
- -
23
2025
- -
- -
- -
- -
23

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-1.25
2024
- -
- -
- -
- -
-1.36
2025
- -
- -
- -
- -
-0.93

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Beijing Chunlizhengda Medical Instruments Co., Ltd. (688236.SS)
Sonova Holding AG (SONVY)
Second Sight Medical Products, Inc. (EYES)
Medacta Group S.A. (MOVE.SW)
Cell Kinetics Ltd. (CKNTF)
Intuitive Surgical, Inc. (0R29.L)
Business
Median Technologies S.A. Median Technologies S.A. develops artificial intelligence-powered imaging solutions and services for oncology clinical trials and precision diagnostics. The company offers iCRO, an end-to-end imaging CRO platform for medical image analysis and management that supports biopharmaceutical companies in phase I through phase III oncology studies with AI-driven insights on patient responses, biomarker discovery, patient selection, disease monitoring, and regulatory submissions; and eyonis, a suite of AI/ML-based software as medical devices (SaMDs) including eyonis LCS for lung cancer screening detection and characterization, eyonis IPN for incidental lung cancer detection, and eyonis HCC for early liver cancer diagnosis, enabling clinicians to improve early detection, diagnostic accuracy, and patient monitoring. Median operates globally with teams in Europe (headquartered in Valbonne, France), the United States (Boston, MA), and China (Shanghai), serving over 80 biopharma clients, more than 2,500 clinical sites across 28 countries, and leveraging a workforce of over 230 professionals from 26 nationalities with expertise in clinical oncology imaging. Founded in 2002, the company recently completed a €23.9 million capital increase in August 2025 to support U.S. commercialization of eyonis LCS following FDA 510(k) application submission, secured a €37.5 million financing line with the European Investment Bank in July 2025, signed a €10 million bond financing agreement with Iris in January 2025, and intensified partnerships with leading U.S. AI diagnostic organizations and global CROs for eyonis suite expansion and iCRO repositioning, extending its cash runway through at least Q4 2026.